How Patient Advocacy Organizations Can Build Funded Partnerships with Biotech Companies
Published: 08 Apr 2026
Patient advocacy organizations sit at one of the most important intersections in healthcare. They have the trust of patients and families. They understand lived experience in ways that no clinical team fully can. And increasingly, biotech companies want access to that trust — for clinical trial recruitment, community education, product development, and real-world evidence.
But the gap between wanting a partnership and building one is enormous.
Most advocacy organizations have never had a formal process for approaching biotech companies. And most biotech companies don’t know which advocacy groups to trust, how to evaluate a potential partner, or how to structure an engagement that goes beyond a one-time sponsorship.
This guide exists to close that gap.
Whether you’re leading a patient advocacy organization looking for your first industry partnership, or a nonprofit professional trying to understand how these relationships actually work, this is a practical breakdown of what it takes — and what it looks like when it’s done well.
Why Biotech Companies Want to Partner with Patient Advocacy Organizations
Before talking about how to build a partnership, it helps to understand what biotech companies are actually looking for — and why.
Access to patient communities
Recruiting for clinical trials is one of the most expensive, time-consuming parts of drug development. Advocacy organizations have built-in community trust that biotech companies cannot replicate quickly on their own. A single introduction from a trusted advocacy leader can accomplish what months of paid outreach cannot.
Real-world insights
Patients and caregivers experience disease in ways that clinical data doesn’t always capture — daily challenges, treatment preferences, quality-of-life tradeoffs. Biotech companies increasingly need this input early in the development process, not after a drug is already approved.
Community social responsibility commitments
Many biotech and pharma companies have CSR goals tied to health equity, community engagement, and diversity in research. Partnerships with advocacy organizations, particularly those serving underrepresented communities, help them meet those commitments in a meaningful way.
Credibility and trust
A patient advocacy organization’s endorsement — or even its association — carries weight with patients, policymakers, and the press. That credibility is valuable, and biotech companies know it.
Understanding these motivations doesn’t mean advocacy organizations should be transactional about the relationship. It means going in with open eyes about what each party brings and what each party needs.
What Biotech Companies Are Looking For in an Advocacy Partner
When a biotech company evaluates a potential advocacy partnership, they are typically assessing a few key things.
Organizational credibility
Do you have a real track record? A clear mission? A community that trusts you? Organizations with active programming, documented impact, and visible leadership are more compelling than those with a website and a 501(c)(3) letter.
Alignment with their therapeutic focus
If a biotech company is developing a treatment for sickle cell disease, they want partners embedded in that community — not a general health nonprofit.
Capacity to deliver
Biotech companies have timelines and budgets. They want to know that the advocacy organization they partner with can show up consistently, communicate professionally, and execute what they agree to.
A succession plan and organizational stability
This is one of the most overlooked factors. Many biotech companies have been burned by partnerships with advocacy organizations that depended entirely on one founder. If a key person leaves, what happens? Organizations that have documented processes and clear leadership structures are far more fundable.
This last point is something Elevate Impact specifically addresses. Our platform and toolkit help advocacy organizations build the internal structures — governance, communication systems, partnership frameworks — that make them credible, sustainable partners.
The Types of Biotech Partnerships Available to Advocacy Organizations
Not all partnerships look the same. Understanding the range of options helps advocacy organizations approach the right opportunities.
Sponsored programming
A biotech company provides funding for a specific program — an educational event, a community health campaign, a patient support resource. This is the most common and lowest-barrier partnership type. It can be valuable, but it tends to be transactional and short-term.
Clinical trial collaboration
The advocacy organization helps recruit participants, educate patients about the trial, and support retention throughout the process. This is a deeper engagement and requires more organizational capacity, but it can be a major source of funding and impact.
Patient advisory roles
Some biotech companies embed advocacy leaders in formal advisory committees — providing input on trial design, patient experience, and community communication. These roles are often paid and can be highly influential.
Co-developed resources
The advocacy organization and the biotech company jointly create educational materials, tools, or frameworks. Both parties benefit from the credibility and reach.
Long-term strategic partnerships
A small number of biotech companies will fund multi-year partnerships with advocacy organizations that go beyond any single program. These are the most valuable and the hardest to secure. They require demonstrated organizational maturity and a track record of delivery.
Step-by-Step: How to Build a Biotech Partnership
Step 1: Know your value before you make the ask
Before approaching any company, get clear on what you bring to the table. Write it down.
- How many patients and families do you serve?
- What communities trust you and why?
- What have you delivered in the past — programs, events, research contributions, policy impact?
- What is your organizational structure and who is on your leadership team?
- Do you have documented processes for partnership management?
If you can’t answer these questions clearly, you’re not ready to pitch. Invest in getting your house in order first.
Step 2: Identify aligned companies
Research is essential. Look for biotech companies whose therapeutic focus matches your disease area. Review their pipeline, their CSR reports, their existing partnerships, and their public statements about community engagement.
LinkedIn is a useful tool for identifying the right contacts — typically people in Clinical Operations & Trial Recruitment, Patient Affairs & Patient Engagement, Medical Affairs & Clinical Development, Health Equity & Community Engagement, Diversity in Clinical Trials, and CSR.
Sales Navigator, which Elevate Impact uses to support our community, makes this research significantly faster.
Step 3: Make a warm introduction when possible
Cold outreach works, but it’s slow and uncertain. The sickle cell and rare disease world is small. Use your network. Ask your board members, advisors, and partner organizations if they have connections at companies you’re targeting.
If you’re an Elevate Impact member, our network and platform are specifically designed to help you find and make these connections.
Step 4: Lead with their priorities, not yours
When you make first contact, don’t start with what you need. Start with what you’ve noticed about their work and where you see alignment.
Something like: “I’ve followed your work in sickle cell disease closely. We serve over [X] families in [geography], and I’ve been thinking about how an organization like ours could add value to what you’re trying to do in the community.”
This approach demonstrates that you’ve done your homework and that you’re thinking about mutual benefit — not just asking for a check.
Step 5: Propose something specific
Vague partnership conversations go nowhere. Come prepared with one concrete idea for how you could work together. It doesn’t have to be your final proposal — it just needs to give the conversation somewhere to land.
Examples: “We’re running a community health day in June for 200 sickle cell patients. Would you be interested in having a presence there?” Or: “We’re developing a patient resource guide and would love your medical affairs team’s input.”
Step 6: Formalize the relationship
Once there’s alignment, put it in writing. Even a simple memorandum of understanding (MOU) protects both parties, sets expectations, and signals that your organization operates professionally.
Be clear about what each party will contribute, what the timeline looks like, and how success will be measured.
Step 7: Deliver and document
Do what you said you would do. Document the outcomes. Capture patient stories, attendance numbers, feedback, and any data that shows impact.
This documentation becomes your proof of delivery for this partner — and your case study for the next one.
Common Mistakes Advocacy Organizations Make
Approaching partnerships too early
If your organization doesn’t have clear programming, documented impact, or basic governance in place, biotech companies will sense it. Build the foundation first.
Asking for too much too soon
A first partnership doesn’t need to be a five-year, $500,000 engagement. Start smaller, deliver well, and let the relationship grow.
Depending on one person
If your partnership lives and dies on the founder’s relationships, it’s fragile. Build institutional relationships, not just personal ones.
Ignoring the relationship between asks
Advocacy organizations sometimes approach a company for funding without having invested in the relationship first. The companies that give the most are usually the ones you’ve served in some way before — through shared events, peer connections, or collaborative projects.
Not measuring anything
“We hosted an event” is not an outcome. “We connected 47 sickle cell patients with their first contact at a clinical research team” is an outcome. Learn to document and communicate impact in terms that resonate with funders.
How Elevate Impact Supports This Work
Elevate Impact was built specifically to reduce the friction in this process.
Our platform connects patient advocacy organizations directly with clinicians, researchers, and industry partners who are looking for the same thing they are — a structured, trustworthy way to collaborate.
Our Cross-Collaborative Toolkit gives advocacy organizations the frameworks to build internal capacity: partnership governance, communication systems, impact measurement, and equity accountability.
Our monthly webinars and roundtables create ongoing learning and connection opportunities in the sickle cell and rare disease community.
And our funding pathway features are designed to help advocacy organizations access the resources they need to sustain their work — including identifying grant opportunities and industry funding programs.
If you’re a patient advocacy organization building toward your first or next biotech partnership, we’d love to be part of that journey.
Frequently Asked Questions
Yes. It is common practice in the rare disease space. Many biotech companies have dedicated community engagement or medical affairs budgets specifically for advocacy partnerships. The amounts range from small event sponsorships to multi-year grants in the hundreds of thousands of dollars.
Most biotech companies prefer to partner with formal nonprofits for legal and tax reasons, particularly for financial arrangements. However, some community-based organizations without 501(c)(3) status have entered into non-financial partnerships. If you’re not incorporated, talk to a legal advisor about your options.
Look for people in medical affairs, community engagement, patient advocacy relations, or CSR. LinkedIn is the most reliable tool for this. Search the company name plus terms like “patient advocacy,” “community engagement,” or “health equity.”
This is a good sign. Before saying yes to anything, make sure you understand what they want, what they’ll provide, and whether the relationship is genuinely mutual. Get any agreement in writing.
Any partnership that involves sharing patient data or personally identifiable information requires explicit consent and should be reviewed by a legal or compliance professional. At minimum, follow HIPAA guidelines. Elevate Impact’s platform is designed with data privacy as a foundational principle.
For smaller sponsorships, timelines can be weeks to a few months. For larger, more formal partnerships, expect three to twelve months of relationship-building, proposals, and internal approvals on the company side. Patience and persistence are required.
Yes. Our platform is specifically designed to be accessible for smaller organizations that don’t have large teams or budgets. Our nonprofit license is priced accordingly, and our toolkit is designed to meet organizations where they are — not where they wish they were.
Building a partnership between a patient advocacy organization and a biotech company is not simple. It requires preparation, research, patience, and the organizational capacity to deliver on what you promise.
But it is absolutely possible — and when it works, the impact on patients and communities is real.
The rare disease space, and the sickle cell community in particular, is small enough that relationships matter enormously. The organizations that invest in building credibility, demonstrating impact, and showing up consistently are the ones that attract the partnerships they deserve.
Elevate Impact exists to make this process more structured, more equitable, and more effective for everyone involved.
If you’re ready to take the next step, we’d love to talk.
